CHINA MEHECO (600056.SS)
- Previous Close
10.33 - Open
10.34 - Bid 10.37 x --
- Ask 10.38 x --
- Day's Range
10.31 - 10.42 - 52 Week Range
9.47 - 13.88 - Volume
6,056,140 - Avg. Volume
10,725,368 - Market Cap (intraday)
15.497B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
28.00 - EPS (TTM)
0.37 - Earnings Date --
- Forward Dividend & Yield 0.23 (2.25%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
--
China Meheco Group Co., Ltd. engages in the pharmaceutical business in China and internationally. The company exports and imports natural medicines, pharmaceutical chemicals, medical equipment, and health products; produces and distributes pharmaceutical and health care products; and operates retail chain pharmacies. Its products include bulk pharmaceutical chemicals antibiotic fermentation and chemical synthesis tablets, injections, capsules, etc.; antibiotics; medicines for the treatment of cardio-cerebrovascular diseases, chronic diseases, and diabetes; antiviral; anti-infectious agents; gastrointestinal drugs; non-steroidal anti-inflammatory drugs; anti-allergic agents; specialty botanicals; western medicine preparations; Chinese patent medicines and herbal pieces; medical equipment and supplies; biological products; chemical raw materials; and nutritional and healthcare products. The company also plants, processes, warehouses, and transports ginseng, licorice, ephedra, rhubarb, rheum officinale, astragalus membranaceus, scutellaria baicalensis, fennel, and other herbs. China Meheco Group Co., Ltd. was founded in 1984 and is based in Beijing, China.
www.meheco.comRecent News: 600056.SS
View MorePerformance Overview: 600056.SS
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600056.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600056.SS
View MoreValuation Measures
Market Cap
15.45B
Enterprise Value
18.88B
Trailing P/E
27.78
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
1.29
Enterprise Value/Revenue
0.56
Enterprise Value/EBITDA
15.91
Financial Highlights
Profitability and Income Statement
Profit Margin
1.65%
Return on Assets (ttm)
2.06%
Return on Equity (ttm)
5.00%
Revenue (ttm)
33.64B
Net Income Avi to Common (ttm)
556.25M
Diluted EPS (ttm)
0.37
Balance Sheet and Cash Flow
Total Cash (mrq)
2.9B
Total Debt/Equity (mrq)
44.12%
Levered Free Cash Flow (ttm)
867.65M